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Abstract Large amounts of new data on the natural his-
tory and treatment of chronic hepatitis B virus (HBV)
infection have become available since 2005. These include
long-term follow-up studies in large community-based
cohorts or asymptomatic subjects with chronic HBV
infection, further studies on the role of HBV genotype/
naturally occurring HBV mutations, treatment of drug
resistance and new therapies. In addition, Pegylated inter-
feron a2a, entecavir and telbivudine have been approved
globally. To update HBV management guidelines, relevant
new data were reviewed and assessed by experts from the
region, and the signiﬁcance of the reported ﬁndings were
discussed and debated. The earlier ‘‘Asian-Paciﬁc consen-
sus statement on the management of chronic hepatitis B’’
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DOI 10.1007/s12072-008-9080-3was revised accordingly. The key terms used in the state-
ment were also deﬁned. The new guidelines include
general management, special indications for liver biopsy in
patients with persistently normal alanine aminotransferase,
time to start or stop drug therapy, choice of drug to initiate
therapy, when and how to monitor the patients during and
after stopping drug therapy. Recommendations on the
therapy of patients in special circumstances, including
women in childbearing age, patients with antiviral drug
resistance, concurrent viral infection, hepatic decompen-
sation, patients receiving immune-suppressive medications
or chemotherapy and patients in the setting of liver trans-
plantation, are also included.
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Introduction
Since the third version of ‘‘Asian-Paciﬁc consensus state-
ment on the management of chronic hepatitis B’’ was
published in June 2005 [1], pegylated interferon-a2a (Peg-
IFN-a2a), entecavir, and telbivudine have been approved
globally and several updated guidelines on chronic hepatitis
B virus (HBV) infection have been published [2–4]. Large
amount of new data on the natural history and treatment of
chronic HBV infection has also become available. These
include long-term follow-up studies in community-based
cohorts and asymptomatic subjects with chronic HBV
infection, further studies on the role of HBV genotypes and
naturally occurring HBV mutations, and treatment of drug
resistance. In addition, new issues such as the ‘‘roadmap’’
concept toward more effective management of the condi-
tion and pharmacoeconomics of drug therapy are emerging.
We have closely followed the progress in the ﬁeld and
invited experts from the Asian-Paciﬁc region to review and
assess relevant new data. The signiﬁcance of the reported
ﬁndings were discussed and debated during a 2-day expert
meeting at Pattaya, Thailand, in November 2007. The 2005
update of the ‘‘Asian-Paciﬁc consensus statement on the
management of chronic hepatitis B’’ [1] was revised
accordingly. The key terms used in the statement were also
deﬁned (Table 1). Then, the revised version was circulated
for further comments and it was reﬁned through electronic
communications among the experts. The revised contents
were presented and discussed at the Asian-Paciﬁc Associ-
ation for the Study of the Liver meeting in Seoul, Korea, in
March 2008. The following is the ﬁnal version of the
updated consensus and recommendations on the manage-
ment of chronic hepatitis B.
Conceptual background
HBV, pathogenesis, and natural course
Chronic HBV infection is a serious clinical problem
because of its worldwide distribution and potential adverse
sequelae. It is particularly important in the Asian-Paciﬁc
region where the prevalence of HBV infection is high. In
this part of the world, the majority of HBV infection
prevalence is acquired perinatally or in early childhood,
and some patients may be superinfected with other viruses
that may inﬂuence the clinical outcomes.
Previous studies revealed the presence of two replication
pathways, namely, episomal and integrated forms, and
reverse transcription process in HBV infection [5]. It has
been recognized that covalently closed circular DNA plays
a key role in the maintenance of chronic HBV infection [6].
As HBV is not usually cytopathogenic by itself, chronic
HBV infection is a dynamic state of interactions among the
virus, hepatocytes, and the host immune system. The nat-
ural course of chronic HBV infection in this geographic
region can be divided into (i) immune-tolerant phase, (ii)
immune clearance phase, and (iii) residual or inactive
phase. HBV reactivation and relapse of hepatitis may occur
in some patients who are in the residual or inactive phase.
Patients in the immune-tolerant phase are usually young,
hepatitis B e antigen (HBeAg) seropositive with high viral
loads ([2 9 10
6 to 2 9 10
7 IU/ml or[10
7–10
8 copies/ml)
but normal serum alanine aminotransferase (ALT) and no
or minimal clinicopathological changes. The results of a
recent 5-year follow-up study have conﬁrmed that adults in
the immune-tolerant phase show minimal disease pro-
gression [7]. However, HBeAg-positive subjects older than
40 years with persistently ‘‘high normal’’ ALT may have
signiﬁcant hepatic necroinﬂammation or ﬁbrosis [8]. Dur-
ing the immune clearance phase, hepatitis activity and even
acute ﬂares with serum ALT levels over 5 times upper
limit of normal (ULN) may occur, and these may some-
times be complicated by hepatic decompensation. These
ALT elevations and hepatitis ﬂares are the result of host’s
immune responses against HBV, such as HLA-class I
antigen restricted cytotoxic T lymphocyte (CTL)-mediated
response against HBV antigen(s) expressed on hepatocytes
with resultant apoptosis and necrosis. Higher ALT levels,
therefore, usually reﬂect more vigorous immune response
against HBV and more extensive hepatocyte damage [9].
This is eventually followed by HBeAg seroconversion to
its antibody (anti-HBe) and/or undetectable HBV-DNA.
The estimated annual incidence of spontaneous HBeAg
seroconversion was 2–15%, depending on factors such as
age, ALT levels, and HBV genotype [9, 10]. Some patients
may experience only transient and mild elevation of serum
ALT levels before HBeAg seroconversion [11]. HBeAg
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123seroconversion is followed by clinical remission (inactive
chronic HBV infection) in the majority of patients. How-
ever, active hepatitis may relapse due to HBeAg
seroreversion or occurrence of HBeAg-negative hepatitis.
The estimated annual incidence of hepatitis relapse was
2.2–3.3% [11, 12], being higher in males, genotypes C
infected, and those who have HBeAg seroconversion after
age 40 [13]. A recent long-term follow-up study
(mean = 12.3 years) involving 1,241 incidentally identi-
ﬁed subjects with inactive chronic HBV infection showed a
lower annual incidence of 1.5%, being signiﬁcantly much
lower in younger patients, especially those younger than
30 years [11]. All these ﬁndings suggest that earlier
HBeAg seroconversion or shorter HBeAg-positive phase is
associated with higher chance of sustained remission.
Asymptomatic HBeAg-negative subjects with HBV-
DNA[2,000 IU/ml may also experience hepatitis ﬂares
and disease progression such as in HBeAg-positive patients
[10–15]. Since the immunopathogenesis of HBeAg-nega-
tive hepatitis is similar to that of HBeAg-positive hepatitis,
this phase can be viewed as a variant of immune clearance
phase.
A prospective study involving 684 patients with chronic
HBV infection showed that cirrhosis developed at an
estimated annual incidence of 2.1%, and that age, the
extent, severity, frequency of ﬂares, and the duration of
hepatic lobular alterations were factors for disease out-
comes and HBV clearance [16]. Patients with chronic HBV
infection with persistent HBeAg seropositivity have an
even higher incidence (3.5% per year) of cirrhosis [17].
One study showed that 23% of the patients with HBeAg-
negative hepatitis progressed to cirrhosis during a follow-
up period of 9 years (range = 1–18.4) [12]. A recent
Korean long-term follow-up study (mean = 120 months)
involving 188 patients (52 HBeAg-negative patients)
showed that age and persistent ALT elevation are inde-
pendent factors for the development of cirrhosis,
decompensation, and hepatocellular carcinoma (HCC)
[18]. HCC develops at an annual incidence of 3–6% in
patients with cirrhosis and far less frequently in
Table 1 Deﬁnition of frequently used terminology
Terminology Deﬁnition
Alanine aminotransferase (ALT)
High normal Serum ALT levels between 0.5 and 1 times upper limit of normal reference (ULN).
Low normal Serum ALT B 0.5 times ULN
Minimally raised Serum ALT levels between 1 and 2 times ULN
Biochemical response Normalization of serum ALT levels
Chronic HBV infection HBsAg seropositive C 6 months
Clinical breakthrough Virologic breakthrough with increased ALT levels or worsening histology
Drug resistance
Genotypic resistance Detection of mutations in the HBV genome, known to confer resistance, which develop during
antiviral therapy
Phenotypic resistance Decreased susceptibility (in vitro testing) to inhibition by antiviral drugs associated with
genotypic resistance
Cross resistance Mutation selected by one antiviral agent that also confers resistance to other antiviral agents
Hepatic decompensation Signiﬁcant liver function abnormality as indicated by raised serum bilirubin level and
prolonged prothrombin time or occurrence of complications such as ascites
Hepatitis ﬂare Increase of serum ALT level to C 5 times ULN
Inactive chronic HBV infection HBsAg (+) anti-HBe (+) with persistent normal serum ALT and HBV-DNA\2,000 IU/ml
(10
4 copies/ml)
Undetectable serum HBV-DNA Serum HBV-DNA levels below detection limit of a PCR-based assay
Virological response
Maintained virologic response Undetectable serum HBV-DNA and HBeAg seroconversion, if applicable, during therapy
Primary treatment failure Reduction of serum HBV-DNA\1 log IU/ml at 12 weeks of oral antiviral therapy
in a compliant patient
Viral breakthrough [1 log IU/ml increase in serum HBV-DNA from nadir of initial response during therapy
as conﬁrmed 1 month later
Secondary treatment failure Viral breakthrough in a compliant patient (due to drug resistance)
Sustained virologic response Serum HBV-DNA\2,000 IU/ml (10
4 copies/ml) and HBeAg seroconversion, if applicable,
for at least 6 months after stopping therapy
Complete response Sustained virologic response with HBsAg seroclearance
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123noncirrhotic patients [12, 19, 20]. Seropositivity for
HBeAg and/or HBV-DNA[2,000 IU/ml are signiﬁcant
risk factors for cirrhosis and HCC development, even in
asymptomatic subjects with chronic HBV infection [21–
25].
Spontaneous HBsAg seroclearance may occur after
HBeAg seroconversion. A recent 11-year follow-up study
in 1,965 asymptomatic anti-HBe positive subjects
[age = 16–76 years (median = 34)] showed an annual
HBsAg seroclearance rate of 1.2%. The cumulative HBsAg
seroclearance rate was 8% at 10 years, increased dispro-
portionately to 25% at 20 years, and 45% at 25 years of
follow-up [26] HBsAg seroclearance usually confers
excellent prognosis [27]. However, HCC may still occur,
although at a very low rate if cirrhosis has already devel-
oped before HBsAg seroclearance [27, 28].
Hepatitis B virus has been classiﬁed into at least eight
genotypes on the basis of an intergroup divergence of 8%
or more in the complete genome nucleotide sequence.
Subtypes are identiﬁed within some genotypes, but their
clinical signiﬁcance remains to be determined. Each
genotype has its distinct geographical and ethnic distribu-
tion, worldwide and within the Asian-Paciﬁc region. HBV
genotypes B and C are prevalent in East and South-East
Asia, the Paciﬁc Islands, and Pakistan, whereas HBV
genotypes D and A are prevalent in India and genotype A
in the Philippines. HBV genotype D is also found in the
Paciﬁc Islands. HBV genotypes B and C are prevalent in
highly endemic areas where perinatal or vertical trans-
mission plays an important role in spreading the virus,
whereas genotypes A, D, E, F, and G are frequently found
in areas where the main mode of transmission is horizontal.
The clinical signiﬁcance and virologic characteristics of
HBV genotypes have only been reliably compared between
genotypes B and C or genotypes A and D. In general,
genotype B is associated with less progressive liver disease
than genotype C, and genotype D has a less favorable
prognosis than genotype A [29]. A recent study in 1,536
Alaskan natives with chronic HBV infection has shown
that the median age for HBeAg clearance was less than
20 years for genotypes A, B, D, and F, but more than
40 years for genotype C, and that patients with genotypes
C and F have signiﬁcantly more frequent HBeAg reversion
and higher risk of HCC [30]. Several studies have shown
that genotype B is associated with spontaneous HBeAg
seroconversion at a younger age, less active liver disease,
slower progression to cirrhosis, and less frequent devel-
opment of HCC than genotype C [10, 22, 29–34]. HBV
genotype B has been shown to induce a greater Th1 and
lesser Th2 response than genotype C, leading to a higher
chance of HBeAg seroconversion [35]. A study from India
indicated that genotype D is more often associated with
HBeAg-negative chronic HBV infection and more severe
diseases and may predict the occurrence of HCC in young
patients [36]. It has also been shown that recombinant
genotypes lead to more severe disease.
Due to the spontaneous error rate of viral reverse tran-
scription, naturally occurring HBV mutations arise during
the course of infection under the pressure of host immunity
or speciﬁc therapy. Several HBV strains including muta-
tions in precore, core promoter, and deletion mutation in
pre-S/S genes have been reported to be associated with the
pathogenesis of fulminant or progressive liver disease,
including cirrhosis and HCC [29]. Patients harboring HBV
genotype C have a higher HBV-DNA level, higher fre-
quency of pre-S deletions, higher prevalence of core
promoter A1762T and/or G1768/A mutations, and
A1762T/G1764A double mutations than patients infected
with HBV genotype B and have a signiﬁcantly higher
chance of developing HCC [21, 25, 29, 34, 37, 38]. A
recent study revealed that a complex mutation pattern
rather than a single mutation was associated with disease
progression [38]. The role of these naturally occurring
HBV mutations in the pathogenesis of liver disease pro-
gression requires further studies.
Concurrent infection with other virus(es)
Hepatitis B virus, hepatitis C virus (HCV), hepatitis delta
virus (HDV), and human immunodeﬁciency virus (HIV)
share similar transmission routes. Therefore, concurrent
infection with these viruses may occur and complicate the
natural course of chronic HBV infection. In general, con-
current infection with these viruses usually results in more
severe and progressive liver disease and thus needs treat-
ment [39].
Goals of treatment for chronic HBV infection
ItisnowclearthatactiveHBVreplicationisthekeydriverof
liver injury and disease progression, thus sustained viral
suppression is of paramount importance [40]. Therefore, the
primary aim of treatment for chronic HBV infection is to
permanently suppress HBV replication. This decreases
infectivity and pathogenicity of the virus. Reducing the
pathogenicity of the virus results in reduced hepatic necro-
inﬂammation. Clinically, the short-term goal of treatment is
to achieve ‘‘initial response’’ in terms of HBeAg serocon-
version and/or HBV-DNA suppression,ALT normalization,
and prevention of hepatic decompensation; to ensure
‘‘maintained/sustained response’’ to reduce hepatic necro-
inﬂammation and ﬁbrosis during/after therapy. The ultimate
long-termgoaloftherapyistoachieve‘‘durableresponse’’to
prevent hepatic decompensation, reduce or prevent pro-
gression to cirrhosis and/or HCC, and prolong survival.
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Currently, IFN-a, lamivudine, adefovir, entecavir, tel-
bivudine, and PegIFN-a2a have been licensed globally.
Clevudine has been approved in Korea. Thymosin a1 has
also been approved in many countries in Asia.
IFN-based therapy
Conventional IFN Conventional IFN-a has been used for
the treatment of chronic HBV infection for more than two
decades. IFN-a has a dual mode of action: antiviral and
immunomodulatory. Early controlled studies have shown
that a 4- to 6-month course of conventional IFN-a at a dose
of 5 MU daily or 10 MU 3 times weekly achieved HBeAg
loss in approximately 33% of HBeAg-positive patients in
comparison with 12% of controls. Smaller dosage (5–6 MU
3 times weekly) has been used in Asian patients with similar
efﬁcacy. Treatment of longer than 12 months’duration may
improve the rate of HBeAg seroconversion, particularly in
those with lower HBV-DNA levels after 16 weeks of
treatment. Retreatment of relapsed patients with IFN-a
showed a response rate of 20–40%. When HBeAg sero-
conversion to anti-HBe is achieved, it is sustained in more
than 80% of cases [41].
Children with chronic HBV infection and high ALT
levels respond to IFN-a at rates similar to adults. A recent
study involving 108 Italian children, however, showed that
there was no signiﬁcant difference in the overall long-term
outcomes in IFN-a-treated and untreated patients, and no
patient developed end-stage liver disease or HCC during
12 years (range = 5–23) of follow-up [42].
The HBeAg seroconversion rate is lower in patients with
lower baseline ALT levels. This rate may be improved by
corticosteroid priming before IFN therapy. The recovery of
immune function following steroid withdrawal may result
in ALT ﬂares and enhance the effect of IFN. A meta-
analysis involving 790 patients in 13 randomized trials
showed that this approach was associated with signiﬁcantly
more frequent loss of HBeAg (P = 0.03) and HBV-DNA
(P = 0.0008), particularly in Asian patients with lower
ALT levels and when lower dose of corticosteroid was
used [43]. Severe adverse effects have been reported with
this approach in patients with advanced liver disease.
IFN-a therapy resulted in end-of-treatment biochemical
and virological response in up to 90% of patients with
HBeAg-negative hepatitis. Sustained response rates, how-
ever, were disappointing: 10–15% with 4–6 months of
treatment; 22% with 12 months of treatment; and 30% with
24 months of treatment. A study from Taiwan showed that
6–10 months’ IFN therapy in HBeAg-negative patients had
an end-of-treatment response of 57% (vs. 18% of controls)
and 6 months’ sustained response of 30% (vs. 7%).
Long-term follow-up studies suggest that IFN-induced
HBeAg seroconversion is durable, increases over time,
results in less cirrhosis development [17], better overall
survival, and survival free of hepatic decompensation [17,
44]. The incidence of HCC is also lower in treated patients,
especially among responders [17, 40, 45]. High HBsAg
loss rate observed after IFN-a therapy in Italian patients
was not observed in Asian patients [17].
A meta-analysis involving 1,505 cirrhotic patients in
seven trials favored IFN therapy in reducing HCC,
although signiﬁcant heterogeneity of the trials made these
results less conclusive. However, it has been shown that
IFN-a therapy in compensated cirrhotic patients is safe and
even more effective than noncirrhotic patients [20]. This
ﬁnding suggests that the beneﬁt of IFN therapy in reducing
HCC might be evident upon longer follow-up. A subgroup
analysis in a recent long-term follow-up study did show
that HCC incidence was reduced signiﬁcantly in IFN-
treated cirrhotic patients [17].
The main advantage of IFN-a therapy is that a course of
ﬁnite duration may achieve sustained off-therapy response
in a proportion of patients with both HBeAg-positive and
HBeAg-negative chronic HBV infections. However, IFN
treatment is usually associated with adverse effects, espe-
cially inﬂuenza-like symptoms, fatigue, neutropenia,
thrombocytopenia, and depression. These are usually tol-
erable, but may require dose modiﬁcation and premature
cessation of treatment [41].
PegIFN-a In an Asian study, a 24-week course of weekly
PegIFN-a2a (40 kD) gave a higher HBeAg seroconversion
(33% vs. 25%; P[0.05) and combination response
(HBeAg loss, HBV-DNA\5 9 10
5 copies/ml, and nor-
mal ALT) rate (24% vs. 12%; P = 0.036) at 6 months after
the end of treatment than conventional IFN-a2a. This
beneﬁt was noted even in patients with a rather low like-
lihood of response to conventional IFN [46]. In large-scale
phase III international multicenter studies involving 814
HBeAg-positive patients ([85% were Asians) and 564
HBeAg-negative patients ([60% were Asians), PegIFN-
a2a (40 kD) monotherapy 180 lg once weekly for
48 weeks resulted in ALT normalization in 41% and 59%
patients, HBV-DNA\80 IU/ml (\400 copies/ml) in 14%
and 19% patients, and HBsAg seroclearance in 3% and
3% patients, respectively. HBeAg seroconversion occurred
in 32% and HBV-DNA levels were less than 20,000 IU/ml
(\10
5 copies/ml) in 32% of HBeAg-positive patients,
whereas HBV-DNA levels remained less than 4,000 IU/ml
(2 9 10
4 copies/ml) in 43% of HBeAg-negative patients
when assessed 6 months after cessation of therapy. Peg-
IFN-a2a was found to be superior to lamivudine, with
respect to sustained HBeAg seroconversion and HBV-
DNA suppression, in both HBeAg-positive and
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sustained in up to 90% when assessed 3 years after end of
therapy [49]. The 6 months’ sustained HBeAg serocon-
version rate is similar to that obtained after 6 months’
therapy in an earlier phase II study. A 4-arm head-to-head
randomized control study using 90 and 180 lg of PegIFN-
a2a for 6 or 12 months is ongoing.
Several studies using PegIFN-a2b showed similar efﬁ-
cacy [41]. One study showed that peg-IFNa2b was safe and
effective in patients with advanced ﬁbrosis or cirrhosis as
those with early stage of ﬁbrosis [50]. Patients with chronic
HBV infection who are lamivudine refractory and those
who are lamivudine naı ¨ve respond similarly to PegIFN-a2b
therapy [51].
High baseline ALT, low baseline HBV-DNA and
HBeAg levels, and high-grade necroinﬂammatory activity
are predictors of response to IFN and PegIFN-a therapy
[41]. ALT ﬂares followed by decrease in HBV-DNA levels
and decline of HBeAg levels during PegIFN-a therapy
were predictors of response at the end of follow-up [52,
53]. Baseline ALT, baseline HBV-DNA, and HBV geno-
type inﬂuence the combined response (ALT normalization
and HBV-DNA\4 9 10
3 IU/ml [\2 9 10
4 copies/ml])
at 24 weeks posttreatment in patients with HBeAg-nega-
tive chronic HBV infection with a 48-week course of
PegIFN-a2a with or without lamivudine [54].
Studies using conventional IFN therapy have shown that
patients with HBV genotypes A and B infection have a
higher HBeAg seroconversion rate than patients with HBV
genotypes C and D infection, respectively [29]. These
ﬁndings were conﬁrmed by recent studies using PegIFN,
where HBeAg seroconversion occurred more often in
patients with HBV genotypes A (40%–47%) and B (30%–
44%) than those with HBV genotypes C (28%–30%) and D
(20%–25%) infection [46, 55]. Signiﬁcantly better
response in genotype B infected patients (31% vs. 17.5% of
genotype C infected; P\0.05) was observed in earlier
6-month PegIFN-a2a trial [46] but not in the recent
12-month trial [47]. This may suggest that longer PegIFN
therapy may be required to enhance the response of the
patients with more difﬁcult-to-treat situations such as in
genotype C or D infected patients.
IFN combination with other agents Studies using IFN-a
or PegIFN-a and lamivudine combination in comparison
with IFN-a or PegIFN-a or lamivudine monotherapy in
HBeAg-positive and HBeAg-negative patients showed that
combination therapy had greater on-treatment viral sup-
pression and higher rates of sustained response than
lamivudine monotherapy, but there was no difference in
sustained off-treatment response when compared with IFN-
a or PegIFN-a monotherapy [47, 48]. To date, there has
been no large clinical trial that conﬁrms the beneﬁts of
PegIFN-a plus nucleoside or nucleotide analogue therapy
over PegIFN-a monotherapy [41].
Sequential therapy with lamivudine 100 mg daily for
4 weeks followed by PegIFN-a2b 1.0 lg/kg per week for a
further 24 weeks (n = 36 patients) compared with Peg-
IFN-a2b monotherapy for 24 weeks (n = 27 patients) in
patients with HBeAg-positive chronic HBV infection
showed a signiﬁcantly higher rate of HBV-DNA unde-
tectability (\4,700 copies/ml) (50% vs. 14.8%) and higher
rates of HBeAg clearance (38.9% vs. 14.8%) at 6 months
posttherapy [56].
A randomized controlled trial in 96 patients showed that
lymphoblastoid IFN 5 MU in combination with thymosin
a-1 1.6 mg 3 times weekly for 24 weeks increased HBeAg
loss 1 year after the end of treatment with marginal sig-
niﬁcance in comparison with IFN monotherapy (45.8% vs.
28%; P = 0.067) [57].
IFN-based therapy: overall conclusions The advantages
of IFN-based therapy include ﬁnite duration of treatment
with modest response, long-term beneﬁt, and no resistance.
PegIFN may eventually replace conventional IFN because
of higher efﬁcacy and more convenient once weekly
administration. The optimal duration (6 vs. 12 months) of
PegIFN therapy in HBeAg-positive patients is under study.
Perhaps patients infected with HBV genotype C or D may
require longer treatment.
Other immunomodulating agents
Thymosin a-1 A few studies have evaluated the efﬁcacy
of thymosin a-1 (Ta1), an immunomodulating agent that
enhances the Th1 immune response, natural killer T cells,
and CD8
+ CTL activity against HBV. A Taiwanese study
showed that therapy with subcutaneous Ta1 1.6 mg twice
weekly for 6 months resulted in a signiﬁcantly higher
HBeAg seroconversion rate (40% vs. 9% in controls) when
assessed 12 months after the end of therapy [58]. A
6-month therapy in Chinese HBeAg-negative patients also
showed a response rate of 42% (11/26) [59]. Patients
infected with genotype B HBV showed a signiﬁcantly
better response (52%) than patients infected with genotype
C (24%) HBV [60]. A response rate of 22% was also
observed in a Japanese study involving 316 patients,
mostly infected with genotype C HBV [61]. A meta-anal-
ysis including 353 patients from ﬁve trials showed that the
odds ratio for virological response to Ta1 at the end of
treatment, 6, and 12 months posttreatment were 0.56 (0.2–
1.52), 1.67 (0.83–3.37), and 2.67 (1.25–5.68), respectively,
with a signiﬁcantly increasing virological response over
time after discontinuation of thymosin therapy [62]. The
number of patients included in thymosin a-1 trials was
relatively small in comparison with recent trials using
268 Hepatol Int (2008) 2:263–283
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large-scale studies are needed to conﬁrm its efﬁcacy. The
main advantages of thymosin a-1 are ﬁxed duration of
therapy and minimal side effects.
Therapeutic vaccines Various therapeutic vaccines were
used in an attempt to restore the virus-speciﬁc host immune
response. However, none of them demonstrated sufﬁcient
clinical efﬁcacy. In a recent open-label controlled study,
195 HBeAg-positive patients were randomized to receive
12 doses of HBsAg with AS02 adjuvant candidate vaccine
plus lamivudine daily for 52 weeks or lamivudine daily
alone. Despite induction of a vigorous HBsAg-speciﬁc
lymphoproliferative response, cytokine production, and
anti-HBs antibodies, therapeutic vaccination with an ad-
juvanted HBsAg vaccine combined with lamivudine did
not demonstrate superior clinical efﬁcacy than lamivudine
alone [63].
Direct antiviral agents
Lamivudine, adefovir, entecavir, and telbivudine are highly
effective in inhibiting HBV replication and have been
approved worldwide for the treatment of chronic HBV
infection. These agents are prodrugs and need intracellular
activation before they can exert their therapeutic action.
The efﬁcacy of treatment with these four drugs is compared
in Table 2. Clevudine has been approved only in Korea.
Tenofovir and other new nucleoside analogues are in var-
ious stages of appraisal.
Lamivudine Lamivudine, an L-nucleoside analogue, at a
daily dose of 100 mg is effective in suppressing HBV-
DNA with ALT normalization and histologic improvement
in both HBeAg-positive and HBeAg-negative patients [64].
HBeAg seroconversion is achieved in 35–65% of HBeAg-
positive patients after 5 years of therapy; the rate being
proportional to the levels of ALT prior to treatment and
highest in patients with ALT levels over 5 times ULN. This
suggests that patients with a more vigorous immune
response to HBV respond better to the direct antiviral
effect of lamivudine [65]. The HBeAg seroconversion rate
is similar in patients with HBV genotype B or C infection.
Children treated with lamivudine for 1 year with dosages
adjusted for body weight (3 mg/kg) showed similar
response to adults, and the drug has been found to be safe
during 3 years of continuous therapy [66]. In the absence
of HBeAg seroconversion, hepatitis ﬂares may occur if
lamivudine is stopped. Lamivudine can be stopped after
HBeAg seroconversion. Sustained HBeAg seroconversion
to anti-HBe occurs in *80% of patients after cessation of
lamivudine therapy [64]. The durability of response is
Table 2 Comparisons of viral
responses among four antiviral
agents in treatment-naı ¨ve
patients with chronic hepatitis B
a–e Data from same randomized
controlled trials (a: [86]; b: [87];
c: [90]; d: [88]; e: [64])
Abbreviations: *, cumulative
incidence; [], data of untreated
controls; **, HBV-
DNA\1,000 copies/ml
HBV: hepatitis B virus; e:
hepatitis B e antigen; NA: not
available
Lamivudine Adefovir dipivoxil Entecavir Telbivudine
e(+)e ( -)e ( +)e ( -)e ( +)e ( -)e ( +)e ( -)
HBV-DNA (-log)
Year 1 5.4
a 4.5
b 3.6 3.7 6.9
a 5.0
b 5.7
c 4.4
c
5.4
c 4.1
c [1.0] [1.4]
Undetectable
Year 1 36%
a 72%
b 21% 61% 67%
a 90%
b 60%
c 88%
c
40%
c 71%
c [0%] [0%]
Year 2 39%*
d NA NA 71% 80%*
d NA 56%
c 82%
c
39%
c 57%
c
Year 3 20% 40% NA 77%** 89%* NA NA NA
HBeAg seroconversion
Year 1 18%
a NA 12% NA 21%
a NA 23%
c NA
22%
c [6%]
Year 2 26%* NA 29% NA 31%* NA 30%
e NA
25%
e
Year 3 40% NA NA NA NA NA NA NA
Genotypic resistance
Year 1 13%
a 6%
b 0% 0%* 0%
a 0%
b 5%
c 2%
c
11%
c 11%
c
Year 2 38%
d 31% NA 3%* 0%
d NA 25%
e 11%
e
40%
e 26%
e
Year 3 57% 57% NA 11%* *1% NA NA NA
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123particularly low in patients with genotype C HBV infec-
tion, older patients, and if treatment is maintained for less
than 4–8 months after HBeAg seroconversion [67]. Acute
ﬂares of hepatitis may occur in patients with the reap-
pearance of HBeAg and detectable HBV-DNA (HBeAg
seroreversion). In pediatric patients, the durability of
HBeAg seroconversion increased from 82% to more than
90% in those who had received lamivudine for 52 weeks
and more than 2 years, respectively [66].
The antiviral and therapeutic impact of lamivudine in
patients with HBeAg-negative chronic HBV infection is
similar to that in HBeAg-positive patients. Sustained
antiviral response is obtained in only 15–20% of cases after
1 year of treatment [63]. Lamivudine therapy for 6–
12 months resulted in 81% maintained virologic response
in a study involving 85 Taiwanese HBeAg-negative
patients with pretreatment ALT[5 times ULN, and sus-
tained virologic response was observed in 39% of these
patients 12 months after stopping lamivudine therapy [68].
In a study involving 50 Chinese-Canadian patients, 2-year
treatment with lamivudine resulted in maintained virologic
response in 37 (74%) patients. Therapy was stopped in
these 37 patients when undetectable HBV-DNA and nor-
mal ALT levels were documented on three separate
occasions at least 3 months apart. Relapse was noted in
50% of these patients (86% of them infected with genotype
C HBV) 1 year after cessation of therapy [69]. In a Hong
Kong Chinese study, 2-year lamivudine treatment in 89
HBeAg-negative patients showed a maintained complete
response (normal ALT and HBV-DNA\2 9 10
3 IU/ml
[\10
4 copies/ml]) rate of 56% and a sustained response
rate of 26% 6 months posttherapy [70]. These three studies
show that about 50% of the patients who achieved main-
tained response have sustained off-therapy response.
Lamivudine is well tolerated and is safe for use, even in
patients with decompensated cirrhosis [20, 64]. Long-term
therapy in viremic patients with advanced ﬁbrosis or cir-
rhosis delays clinical progression by reducing the rate of
hepatic decompensation and HCC development, even in
patients with low or normal ALT levels [71].
After 6–9 months of lamivudine therapy, viral break-
through may occur following the emergence of HBV
mutations that are resistant to lamivudine. These HBV-
variant species have mutations in the YMDD motif of the
polymerase gene (rtM204I and rtM204V with or without
rtL180M). The incidence increases with increasing dura-
tion of therapy, up to 70% among patients treated with
lamivudine continuously for 5 years. Other factors associ-
ated with the emergence of rtM204 I/V include baseline
HBV-DNA, ALT, and/or hepatitis activity, sex and body
mass index, and initial virologic response. Recent studies
have shown that detectable HBV-DNA at month 6 was
associated with higher resistance rate [64, 70]. The
emergence of genotypic resistance is usually followed by a
more than 1 log increase of HBV-DNA from nadir (viral
breakthrough). With continuation of therapy, ALT eleva-
tion (biochemical breakthrough) occurs in more than 90%
of patients after documented viral breakthrough [72, 73].
Hepatitis ﬂares may develop and can occasionally result in
hepatic decompensation [74]. New and distinct mutants
may be selected during continuing lamivudine therapy and
elicit further hepatitis ﬂares [75]. The initial histologic
improvement may be reversed in patients with rtM204 I/V
[76]. The beneﬁt of long-term therapy in preventing disease
progression in patients with advanced ﬁbrosis or cirrhosis
also decreased after emergence of rtM204 I/V [71, 77]. The
decision on long-term lamivudine therapy must therefore
take into consideration the potential clinical beneﬁts, pos-
sible risk associated with drug-resistant mutations, and the
durability of response after stopping therapy.
Combination therapy using lamivudine with adefovir,
telbivudine, IFN, or PegIFN has not demonstrated signiﬁ-
cant efﬁcacy advantage in controlled trials. These
combinations, however, lower the rates of resistant muta-
tions than lamivudine monotherapy [64]. A pilot study in
30 Taiwanese patients showed that a short course of
prednisolone priming enhanced Th1 response and efﬁcacy
subsequent to lamivudine therapy [78]. ‘‘Lamivudine
pulse’’ therapy has resulted in sustained HBeAg and HBV-
DNA loss in 31% of 27 patients with chronic HBV infec-
tion and normal ALT levels [79]. This approach could be
dangerous in patients with advanced ﬁbrosis or cirrhosis.
Adefovir dipivoxil Adefovir dipivoxil is a synthetic
acyclic adenine nucleotide analogue. It is a potent inhibitor
of HBV reverse transcriptase in the wild-type HBV as well
as in lamivudine-, telbivudine-, and entecavir-resistant
mutants.
Two large international multicenter double-blinded,
placebo-controlled studies have shown that oral adefovir
dipivoxil 10 mg daily for 48 weeks is effective in HBV-
DNA suppression, ALT normalization, and histologic
improvement in patients with both HBeAg-positive and
HBeAg-negative chronic HBV infections. In HBeAg-
positive patients, HBeAg loss and HBeAg seroconversion
increased from 12% (control 6%) after 1 year to 40% after
3 years’ therapy [64]. Up to 240 weeks of adefovir therapy
in naı ¨ve HBeAg-negative patients resulted in HBV-
DNA\200 IU/ml in 67% of patients, ALT normalization
in 69% of patients, improvement in necroinﬂammation in
83% of patients, and regression of ﬁbrosis in 73% of
patients, respectively [80]. Response to adefovir was sim-
ilar in Asian and Caucasian patients. Integrated analysis
from all phase III clinical trials showed that HBV genotype
does not inﬂuence virologic response to adefovir dipivoxil
regardless of HBeAg serostatus [64].
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similar to placebo in patients with compensated chronic
HBV infection. Renal laboratory abnormalities reported
with 30 mg of adefovir dipivoxil were not observed with
10 mg of dosage during the 1-year study period. Reversible
increase in serum creatinine of more than 0.5 mg/dL
(maximum 1.5 mg/dl) was reported in 3% of patients when
therapy was extended to 5 years [80]. Most patients with
decompensated chronic HBV infection, including patients
with pre- and post-liver transplant, have some degree of
underlying renal insufﬁciency. Studies on these patients
showed increases in serum creatinine levels by 0.5 mg/dl
or more from baseline in 16% of them by week 48, 31% by
week 96, and 1% required discontinuation due to renal
failure [64].
Sequenced RT domain of HBV-DNA polymerase iden-
tiﬁed rtN236T and rtA181T/V mutations with decreased
susceptibility to adefovir dipivoxil in patients on adefovir
therapy for more than 1 year. The overall incidence of
adefovir-resistant mutation is low. Integrated incidence rate
was 0%, 3%, and 11%, 18%, and 29% at the end of each
successive year of therapy in HBeAg-negative patients.
HBV-DNA[200 IU/ml (10
3 copies/ml) at week 48 were
predictive of the emergence of adefovir-resistant mutations
(49% vs. 6% of those\10
3 copies/ml) during 192 weeks of
adefovir treatment [80]. Adefovir dipivoxil-resistant
rtN236T mutant remains susceptible to L-nucleoside ana-
logues lamivudine, emtricitabine, telbivudine, and entecavir
in vitro and may argue for their combination in therapy. The
rtA181T/V HBV is resistant to adefovir and all the
L-nucleoside analogues, but sensitive to entecavir [73].
One year of adefovir dipivoxil monotherapy or in
combination with lamivudine reduced serum HBV-DNA
levels in most patients with lamivudine-resistant mutants
(median reduction = 3.6 log10 to 4.6 log10 copies/ml).
Switching to adefovir dipivoxil monotherapy in lamivu-
dine-resistant patients appeared effective and safe, even in
patients with liver decompensation [81]. The rate of
resistant mutation, however, is higher under such circum-
stances (up to 30% by the end of year 2) than adefovir
monotherapy in lamivudine-naı ¨ve patients [82]. A 3-year
study of 145 lamivudine-resistant HBV-infected patients
showed that add-on adefovir led to undetectable HBV-
DNA in 80% and normal ALT in 84% of patients, and none
developed virologic and clinical breakthrough during 12–
74 months of therapy [83]. Add-on adefovir in patients
with HBV-DNA [10
7 copies/ml is associated with insuf-
ﬁcient virologic response [82, 84], and should therefore be
instituted as soon as genotypic resistance is detected and
before the serum HBV-DNA levels increase to a level too
high to be suppressed successfully [85].
The high genetic barrier to resistance and the ability to
suppress most lamivudine-resistant mutants (rtM204 V/I)
makes adefovir dipivoxil an attractive drug. Renal toxicity
is rare with the dose of 10 mg and few patients had sig-
niﬁcant elevation of serum creatinine levels of more than
0.5 mg/dl in clinical studies. Caution must be exercised in
treating patients with renal impairment.
Entecavir Entecavir is a cyclopentyl guanosine analogue
with potent selective inhibition of the priming, DNA-
dependent synthesis, and reverse transcription functions of
HBV polymerase. In a viral kinetic study comparing ent-
ecavir to adefovir in HBeAg-positive patients with high
viral load, entecavir showed signiﬁcantly greater HBV-
DNA reduction as early as day 10, HBV-DNA reduction
was -6.23 log versus -4.42 log at week 12 and -7.28 log
vs. -5.08 log at week 48, respectively [64]. Pivotal phase
III randomized lamivudine controlled trials showed that
1-year entecavir (0.5 mg/day) is superior to lamivudine in
reducing HBV-DNA in both HBeAg-positive (-6.9 log vs.
-5.4 log; P\0.0001; HBV-DNA\300 copies/ml in
67% vs. 36%) [86] and HBeAg-negative patients (-5.0 log
vs. -4.5 log; P\0.001; HBV-DNA\300 copies/ml in
90% vs. 72%) [87]. HBeAg seroconversion rate was 21%
(68% in patients with pretherapy ALT[5 times ULN).
Extending entecavir therapy to 96 weeks for partial
responders at week 48 resulted in an increase in the rate of
HBV-DNA\60 IU/ml (\300 copies/ml) to 74%, ALT
normalization increased to 79%, and a cumulative HBeAg
seroconversion rate of 31% [88]. The corresponding rate
was 91%, 86%, and additional 16%, respectively, after
extending entecavir therapy to 192 weeks [64].
Switching to entecavir monotherapy (1 mg/day) is ini-
tially effective in lamivudine-resistant patients (-5.11 log
vs. -0.48 log reduction in lamivudine controls; P\0.001)
and safe without risk of ALT ﬂares. HBeAg loss was
documented in 10% of lamivudine-resistant HBeAg-posi-
tive patients (vs. 3% in lamivudine controls; P = 0.028)
[89]. Entecavir has a high genetic barrier, and drug resis-
tance requires at least three mutations including rtL180M
and rtM204 V, plus a mutation at one of the following
codons: rtT184, rtS202, and/or rtM250 [73]. Therefore,
entecavir therapy in lamivudine-refractory patients is
associated with a higher entecavir resistance rate [88, 89].
The cumulative probability of a virologic breakthrough
from entecavir resistance through 4 years is at least 0.8% in
lamivudine-naı ¨ve patients and 39.5% in lamivudine-
refractory patients [64, 73].
Telbivudine Telbivudine is an orally bioavailable
L-nucleoside with potent and speciﬁc anti-HBV activity. In
clinical trials, telbivudine gave more potent HBV sup-
pression than lamivudine or adefovir. In the phase III
randomized lamivudine controlled trial in 1,371 patients
(446 HBeAg negative, 1,040 Asians), signiﬁcantly greater
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evident by week 12 (-5.71 log vs. -5.42 log in HBeAg-
positive patients and -4.36 log vs. -4.08 log in HBeAg-
negative patients). HBV-DNA reduction persisted through
week 52 with greater histologic response, larger propor-
tions of patients with undetectable HBV-DNA (60.0% vs.
40.4% in HBeAg-positive patients and 88.3% vs. 71.4% in
HBeAg-negative patients), and less resistance (5.0% vs.
11% in HBeAg-positive patients and 2.3% vs. 10.7% in
HBeAg-negative patients) than lamivudine. The C-domain
mutation rtM204I and the B-domain mutation rtA181T/V
are the common mutations associated with telbivudine
resistance. The HBeAg seroconversion rate was similar
between telbivudine- and lamivudine-treated patients. The
study also showed that 41% of HBeAg-positive patients
with undetectable HBV-DNA at week 24 underwent
HBeAg seroconversion by week 52 versus 4% for patients
with HBV-DNA[2,000 IU/ml at week 24. Only 1% of
HBeAg-positive patients with undetectable HBV-DNA and
2% of patients with HBV-DNA\200 IU/ml (\10
3 copies/
ml) at week 24 developed drug resistance by week 52,
whereas 11% of patients with HBV-DNA[10
4 copies/ml
at week 24 became resistant at week 52. The corresponding
ﬁgures for drug resistance in HBeAg-negative patients was
0%, 6%, and 30%, respectively [90]. Two-year telbivudine
therapy was signiﬁcantly superior to lamivudine in both
HBeAg-positive and HBeAg-negative patients for all direct
measures of antiviral effect, including serum HBV-DNA
reduction from baseline (-5.7 vs. -4.4 in HBeAg-positive
patients and -5.0 vs. -4.2 in HBeAg-negative patients),
PCR negativity (56% vs. 39% in HBeAg-positive patients
and 82% vs. 57% in HBeAg-negative patients), HBeAg
seroconversion in patients with ALT C2 times ULN (36%
vs. 27%; P = 0.022), and viral resistance (25% vs. 40% in
HBeAg-positive patients and 11% vs. 26% in HBeAg-
negative patients; P\0.001). Week 24 HBV-DNA levels
also emerged as a strong predictor of week 104 efﬁcacy
outcomes [64].
In another 1-year randomized adefovir controlled trial in
135 HBeAg-positive patients, signiﬁcantly greater HBV-
DNA reduction with telbivudine was evident at week 24
(-6.30 log vs. -4.97 log, undetectable HBV-DNA in 39%
vs. 12%; C3 log copies/ml in 50% vs. 78% of patients) and
week 52 (-6.56 log vs. -5.99 log; undetectable HBV-
DNA 60% vs. 40% of patients). The HBeAg seroconver-
sion rate at week 52 of treatment was also higher in
telbivudine-treated patients than in adefovir-treated
patients (28% vs. 19%; P = 0.34). A predictive analysis of
response showed that week 24 serum HBV-DNA\200
vs. C 200 IU/ml (\3 log10 vs. C3 log10 copies/ml) corre-
lated with undetectable HBV-DNA (95% vs. 24%) and
HBeAg seroconversion rate (41% vs. 14%) at year 1.
Patients with viral breakthrough at year 1 had HBV-
DNA[200 IU/ml ([3 log10 copies/ml) at week 24 [91].
Increase in creatine kinase levels was observed more
frequently in recipients of telbivudine, of whom 7.5% (vs.
3.1% in lamivudine-treated controls) had grade 3 or 4
elevation (a level of[7 times ULN). Two-thirds of grade 3
or 4 creatine kinase elevations decreased spontaneously to
grade 2 or lower during continued treatment. Symptomatic
myopathy was reported in 1 patient after 11 months of
telbivudine therapy, and resolved over a period of 9–
12 months after stopping telbivudine [90].
Other emerging direct antivirals Clevudine is a pyrimi-
dine analogue with potent and sustained antiviral activity
against HBV. Clevudine 30 mg/day for 24 weeks resulted
in end-of-treatment HBV-DNA reduction of 5.10 log10
copies/ml, undetectable HBV-DNA in 59%, ALT normal-
ization in 68.2%, and HBeAg loss in 24% of 243 HBeAg-
positive patients [92]. The same regimen resulted in end-
of-therapy HBV-DNA reduction of 4.25 log10 copies/ml,
undetectable HBV-DNA in 92%, and ALT normalization
in 75% of 86 HBeAg-negative patients; HBV suppression
sustained as HBV-DNA was 3.11 log10 copies/ml, with
undetectable HBV-DNA in 80.3% and normal ALT in
70.5% of patients 24 weeks after stopping clevudine [93].
No signiﬁcant difference was reported in these efﬁcacy
parameters among the patients with different pretreatment
ALT levels [92]. Substitutions rtA181A/T and rtA181T
without viral breakthrough were detected in 5 (2.7%) of the
182 HBeAg-positive patients [92], but none in HBeAg-
negative patients [93].
Tenofovir disoproxil fumarate is an acyclic adenine
nucleotide that exerts a strong and early suppression of
HBV with or without lamivudine-associated mutations. It
has been approved for use in the treatment of HIV infec-
tion. Tenofovir 300 mg/day is more potent than adefovir
10 mg/day but without comparable renal toxicity. Clinical
studies have shown that administration of tenofovir 300 mg
daily has stronger antiviral effect against lamivudine-
resistant HBV than adefovir 10 mg daily [94, 95]. Phase III
randomized adefovir controlled trial in HBeAg-positive
patients has shown that tenofovir has better efﬁcacy than
adefovir with respect to histologic improvement (74% vs.
68%), HBV-DNA reduction to less than 400 copies/ml
(76% vs. 13%; P\0.001), ALT normalization (69% vs.
54%; P = 0.02), and HBeAg seroconversion (21% vs.
18%; P = 0.36). Tenofovir also achieved combined viro-
logic and histologic response in a higher proportion of
HBeAg-negative patients (71% vs. 49%; P\0.001) [96].
Tenofovir appears to be a very promising drug and is likely
to get approval for use in the treatment of chronic HBV
infection and replace adefovir in the near future.
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sions The successive generation of nucleos(t)ide
analogues has improved potency and raised genetic barrier
to resistant mutations (Table 2). Although there is no head-
to-head comparison among these 4 drugs, the results of
published pivotal trials suggest that entecavir is the most
potent agent, followed by telbivudine, lamivudine, and
adefovir in terms of HBV-DNA reduction during a 1-year
treatment period. Histologic improvement and documented
regression of advanced ﬁbrosis and cirrhosis among the
responders is an important achievement. Reduction in the
progression of disease and HCC development after 3 years
of lamivudine therapy for patients with advanced ﬁbrosis is
a proof for therapeutic aim. Increased antiviral potency of
these drugs, however, does not correlate with increase in
HBeAg loss or HBeAg seroconversion. Resistance is a
major concern during long-term therapy. The incidence at
1 and 2 years is highest with lamivudine, followed by
telbivudine, then adefovir and tenofovir, and almost none
with entecavir. In choosing a direct antiviral agent to ini-
tiate therapy, resistance proﬁle is a crucial factor to
consider other than the potency and cost. The ‘‘roadmap’’
concept for using on-treatment HBV-DNA level as a pre-
dictor for drug resistance may be useful when patients are
treated with agents with high resistance rate [97]. Phar-
macoeconomic studies would be helpful in individual
countries in Asia-Paciﬁc region because cost is one of the
most important factors in the choice of drug for initial
therapy [98].
Special groups of patients
Pregnancy
IFN-based therapy is contraindicated in pregnancy because
of its antiproliferative effect. Among the direct antiviral
agents, telbivudine is classiﬁed as category B drug (no risk
in animal studies, but unknown in human), whereas lami-
vudine, adefovir and entecavir are classiﬁed as category C
drugs (teratogenic in animal, but unknown in human) by
the US FDA [99]. The stage of the mother’s liver disease
and potential beneﬁt of treatment must be weighed against
the small risk to the fetus. IFN-based therapy is preferable
in women in the childbearing age, and pregnancy is dis-
couraged during IFN therapy. No ﬁrm recommendation can
be made on the use of nucleosi(t)de analogues in the pre-
vention of transmission from viremic mothers because of
the lack of sufﬁcient data and conﬂicting results with
regard to efﬁcacy and adverse events. Women with chronic
HBV infection who become pregnant while on direct
antiviral therapy can continue treatment with category B
drugs [3].
Patients with concurrent HCV, HDV, or HIV infection
Patients with concurrent HCV, HDV, or HIV infections
tend to have a higher incidence of cirrhosis, HCC, and
mortality. Insufﬁcient data exist to reach ﬁrm conclusions
on the management of patients with HCV and/or HDV
infections. However, it is generally agreed that the domi-
nant virus should be identiﬁed before designing therapeutic
strategy. If HBV is dominant, treatment should be aimed
toward this virus. If HCV is dominant, standard IFN or
PegIFN therapy in combination with ribavirin can achieve
a sustained HCV clearance rate comparable to that in HCV
monoinfection. Lamivudine is ineffective in patients with
chronic HDV infection. Small randomized controlled trials
using 3–9 MU of IFN for 3–24 months showed a bio-
chemical and virologic response in up to 70% of the
patients with chronic HDV infection. Sustained response
was noted in less than 20% of patients. Higher doses of
IFN-a (9 MU thrice weekly) for 12 months have been
found to inhibit HDV-RNA, normalize ALT, and improve
histology in patients with chronic HDV infection. ALT
response sustained in 50% of the patients and the long-term
outcomes and survival improved signiﬁcantly even in
patients with liver cirrhosis [100]. IFN in combination with
lamivudine therapy tends to increase response rate com-
pared with IFN monotherapy [101]. Two small studies
using weight-based PegIFN-a2b (1.5 lg/kg weekly) for 6
and 12 months, respectively, showed discrepant results
[100].
In patients with concurrent HIV infection and CD4
+
counts of more than 500 cells/lL, treatment options include
agents without anti-HIV activity: IFN, adefovir, and tel-
bivudine. IFN-based therapy or adefovir is preferred
because of the absence of resistance in the former and a
low resistance proﬁle in the later. Both lamivudine and
tenofovir are active against HBV and HIV and can be used
in combination as part of the highly active antiretroviral
therapy (HAART) in patients who need both anti-HBV and
anti-HIV therapies. In patients with low CD4 count and
active liver disease, HBV should be treated ﬁrst to avoid
the risk of immune reconstitution syndrome that usually
occurs with HIV treatment.
Patients with hepatic decompensation
Patients with hepatic decompensation should be considered
for treatment because it may both improve their clinical
status and even remove them from liver transplant lists.
IFN does not beneﬁt patients with Child’s B or C cirrhosis.
Moreover, signiﬁcant adverse effects due to serious bac-
terial infections and possible exacerbation of liver disease
occur even with low doses. Lamivudine is well tolerated
and results in clinical improvement or stabilization,
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6 months’ treatment [102, 103]. Early treatment is rec-
ommended to improve outcomes. Selection of resistant
mutants with resultant biochemical dysfunction, reduction
in efﬁcacy, and rapid clinical deterioration in this group of
patients is a real concern with early treatment [20]. Adding
adefovir to 128 lamivudine-resistant patients with decom-
pensated cirrhosis and 196 lamivudine-resistant patients
with recurrent HBV infection after liver transplantation
was associated with 3–4 log reduction in serum HBV-DNA
levels throughout the treatment period [104]. However,
renal dysfunction is a potential problem in patients with
hepatic decompensation. Close monitoring of renal func-
tion is, therefore, required if this drug is being used for
such patients. Entecavir, telbivudine, and tenofovir are
being evaluated as a primary treatment modality in patients
with decompensated liver disease. Given the similar
mechanisms of action and safety proﬁle, the more potent
entecavir, telbivudine, and tenofovir are anticipated to be
more effective than or at least as effective as lamivudine in
this clinical setting with lower or nearly no incidence of
drug resistance and no problem with nephrotoxicity.
Pediatric patients
Children with elevated ALT levels respond to IFN and
lamivudine in a similar manner to adults. A small study in
children and adolescents (aged 2–17) showed that adefovir
is generally well tolerated at a dose of 0.3 mg/day for those
aged 2–11, and 10 mg for those aged 12–17 [105]. Newer
agents such as PegIFN and other nucleos(t)ide analogues
have not yet been studied, but are likely to be as effective
in children as in adults with chronic HBV infection. Long-
term safety and drug resistance are more important con-
cerns in children than in adults. As already mentioned,
recent long-term follow-up study showed that IFN therapy
provided little beneﬁt in comparison with untreated chil-
dren [42]. Therefore, drug therapy is usually not
recommended in pediatric patients because of the apparent
lack of long-term beneﬁts and attending risks of starting
drug therapy, unless there is an absolute indication such as
in the setting of ensuing or overt hepatic decompensation.
Patients on immunosuppression or chemotherapy
Reactivation of HBV replication with decompensation has
been reported in 20–50% of patients with chronic HBV
infection undergoing cancer chemotherapy or immuno-
suppressive therapy, especially those containing high-dose
steroid regimen. Reactivation commonly occurs after the
ﬁrst 2–3 cycles of chemotherapy. High viral load at
baseline is the most important risk factor for HBV reac-
tivation [106]. HBV reactivation following transarterial
chemoembolization was also observed in 34% of 83
patients with HCC [107]. Lamivudine is effective in the
treatment of HBV reactivation in HBsAg-positive organ
transplantation recipients and cancer patients undergoing
chemotherapy, particularly if it is used preemptively.
Prophylactic use of lamivudine within 1 week before the
start and continued at least 12 weeks after end of che-
motherapy, and when white blood cell count has
normalized, can reduce HBV reactivation frequency and
severity of ﬂares and improve survival [106].
The impact of immunosuppressive therapy on patients
with occult HBV infection is poorly characterized. In a
recent study involving 244 consecutive HBsAg-negative
lymphoma patients who received chemotherapy, 8 (3.3%)
developed de novo HBV-related hepatitis and 3 with ful-
minant hepatic failure, following a 100-fold increase in
serum HBV-DNA levels. These patients responded to
lamivudine, but one died of hepatic failure. These ﬁndings
suggest that even in an HBV endemic area, the occurrence
of de novo HBV-related hepatitis after chemotherapy is
low. It was suggested that HBsAg-negative patients,
especially those receiving rituximab plus steroid-contain-
ing regimen, should be closely monitored to facilitate
early commencement of nucleoside/nucleotide analogues
[108].
Liver transplantation for chronic HBV infection
Liver transplantation has become a cost-effective treatment
of liver failure and HCC with excellent 5-year survival.
Improving economies and live related liver donation have
allowed a rapid expansion of liver transplantation within
the Asia-Paciﬁc region where hepatitis B is the most
common indication for both acute and chronic liver failure.
Acute or chronic HBV infection accounts for most cases of
acute liver failure in this region, whereas more than 80% of
cases of chronic liver failure and HCC are caused by
chronic HBV infection. Although HBV recurrence can be
prevented in 60% of cases by high-dose (10,000 U/month)
intravenous hepatitis B immunoglobulin (HBIg), this
therapy is prohibitively expensive (US$50,000 per annum,
lifelong) and is ineffective in transplant candidates with
detectable HBV-DNA. Suppression of pretransplant viral
replication signiﬁcantly reduces the risk of posttransplant
recurrence. In addition, viral suppression rescues some
patients with decompensated cirrhosis, thereby removing
the need for future transplant [103].
Antiviral therapy should be commenced in all potential
liver transplant candidates with decompensated HBV cir-
rhosis and detectable HBV-DNA. However, posttransplant
HBV recurrence may still occur despite antiviral prophy-
laxis and is usually due to lamivudine resistance [1].
Adefovir and entecavir are available for rescue therapy for
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minimize the problems of drug resistance. Combination
lamivudine/HBIg prophylaxis reduces recurrence rates of
HBV infection to less than 5% and is associated with 5-
year patient and graft survival rates of 85% and 80%,
respectively. A recent long-term (median = 62 months)
follow-up study involving 147 patients has shown that
lamivudine plus low-dose intramuscular HBIg (400–800 U
daily for 1 week, then monthly) appears as effective as
lamivudine plus high-dose intravenous HBIg, but is less
than 10% the cost (US$4,000) [109]. A recent study sug-
gested that late HBIg substitution by adefovir (at least
12 months posttransplant) can prevent late HBV recurrence
at less cost [110] In a prospective open-labeled study,
lamivudine plus adefovir combination from the time of
listing was well tolerated, prevented lamivudine resistance
prior to transplant, rescued some patients from the need for
transplantation, and prevented recurrent HBV infection
following liver transplantation, regardless of baseline
HBV-DNA status [111] Both studies demonstrate that
lamivudine plus adefovir combination prophylaxis has
similar efﬁcacy to current lamivudine plus HBIg prophy-
laxis but without the cost and inconvenience of long-term
monthly HBIg administration. There is emerging data that
HBIg ± lamivudine prophylaxis can be replaced by lami-
vudine monotherapy 12 months posttransplant in certain
‘‘low-risk’’ patient groups. These include patients who
were HBV-DNA negative (hybridization assay) before
pretransplant lamivudine therapy was started and patients
with sustained protective levels of anti-HBs production
following posttransplant vaccination.
Adoptive immune transfer may result in de novo anti-
HBs production in recipients of live related liver graft from
an HBV immune donor. A liver from anti-HBc(+) donor
carries a signiﬁcant risk of de novo HBV infection if
transplanted into an HBV-naı ¨ve recipient. This risk
becomes negligible if the recipient receives long-term
prophylaxis with either lamivudine or HBIg or if the
recipient is seronegative for HBsAg but positive for anti-
HBs.
Issues and recommendations
Based on this background information, the following issues
and recommendations for management of chronic HBV
infection are listed. The recommendations were based on
evidences graded as I (at least 1 well-designed, randomized
control trial), II (well-designed cohort or case-controlled
studies), III (case series, case reports, or ﬂawed clinical
trials), and IV (opinions of respected authorities based on
clinical experience, descriptive studies, or reports of expert
committees).
General management
Before active therapy, a thorough evaluation of the patient
is essential. A complete blood cell count, biochemical tests,
and HBV replication status should be part of the initial
evaluation. Besides drug therapy directed at liver disease,
counseling of the patient is also very important and even
crucial for a successful antiviral therapy. This should
include information on the infectivity/transmission of HBV
and preventive measures for family members and sexual
contacts (e.g., vaccination); advice on lifestyle such as
activity, diet, alcohol use, risk behaviors, and factors that
predispose to superinfection with other hepatitis virus(es)
and their prevention; the importance and need for careful
follow-up and long-term monitoring, and possible therapy.
Health-related quality of life assessment has shown that
patients with chronic HBV infection attribute a wide range
of negative psychological, social, and physical symptoms
to their condition even in the absence of cirrhosis or cancer
[112]. These symptoms should be considered in the coun-
seling process. The indications, risks/beneﬁts, advantages/
disadvantages, cost, and possible problems of each thera-
peutic option should be explained in detail. The therapy
should be tailored for individual needs. Careful assessment
on an individual basis, including likelihood of response and
economic factors of individual patients, is absolutely
essential before starting therapy. HBV genotyping may be
considered, but is not mandatory.
Recommendation 1: Thorough evaluation and counsel-
ing are mandatory before considering drug therapy (II).
Indications for treatment
Available information suggests that patients with persis-
tently normal ALT levels usually have minimal histologic
changes and respond poorly, in terms of HBeAg serocon-
version, when treated with currently available drugs.
Therefore, no drug treatment is recommended for this
group of patients unless they have evidence of advanced
ﬁbrosis or cirrhosis [113]. However, they should be fol-
lowed up every 3 months for the ﬁrst year, and then
monitored every 3 months if HBeAg positive and every
6 months if HBeAg negative. Surveillance for HCC using
ultrasonography and serum a-fetoprotein every 3–6 months
is also important for high-risk HBV-infected persons
(male, age[40, cirrhotic, positive family history of serious
liver disease) [114]. Patients with active HBV replication
(positive HBeAg and/or HBV-DNA) and raised ALT levels
are candidates for treatment. Liver biopsy is recommended
before therapy to assess the necroinﬂammatory grade,
determine the ﬁbrotic stage, and exclude other possible
causes of raised ALT levels as a guide to the indication for
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123antiviral treatment. A liver biopsy should be considered in
patients older than 40 [115], especially those with high
normal ALT levels [8].
Recommendation 2: Patients with viral replication but
persistently normal or minimally elevated ALT levels
should not be treated, except in patients with advanced
ﬁbrosis or cirrhosis. They need adequate follow-up and
HCC surveillance every 3–6 months (I).
Recommendation 3: Prior to therapy, liver biopsy is
recommended in patients with HBV replication and raised
ALT levels, or those with high normal ALT levels and older
than 40 (II).
Time to start treatment (Figs. 1–3)
Treatment may be started if patients have persistently
elevated ALT level C2 times ULN (at least 1 month
between observations).
HBV DNA <20,000 
IU/mL
(<105 copies/mL)
• No treatment
• Monitor HBV DNA, HBeAg, 
ALT/3-6 months
• No treatment
• Monitor HBV DNA, 
HBeAg, ALT/1–3 
months
• Liver biopsy if patient >40 years
• Treat if moderate or greater 
inflammation or fibrosis on biopsy
• Treatment if persistent 
(3~6 months) or has 
concerns for hepatic 
decompensation
• Interferon- based therapy, 
entecavir, telbivudine
lamivudine, adefovir, are 
all first-line options
• Treatment indicated
• If HBV-DNA < 2x106 IU/ml,
may choose to observe 
closely for 3 months for 
seroconversion if no 
concerns for hepatic 
decompensation
• Interferon- based therapy;
entecavir, telbivudine or 
lamivudine recommended, 
particularly if there is 
concern for hepatic 
decompensation
Monitor HBV DNA, 
HBeAg, ALT/1-3 months 
post-therapy
Consider other 
strategies 
(including LT)
HBeAg-Positive
ALT >5 × ULN ALT 1-2 × ULN ALT 2-5 × ULN ALT Normal ALT Normal
HBV DNA ≥20,000 IU/mL
(≥105 copies/mL)
• No treatment
• Monitor HBV DNA, 
HBeAg, ALT/ 
3 months
Response Non-response Patients at risk: HCC surveillance
• AFP and ultrasonography/6 months
Fig. 1 Algorithm for the
management of hepatitis B e
antigen (HBeAg)-positive
patients with chronic hepatitis B
infection. AFP:
alphafetoprotein; ALT: alanine
aminotransferase; HBV:
hepatitis B virus; HCC:
hepatocellular carcinoma; ULN:
upper limit of normal; LT: liver
transplantation
HBV DNA <2,000 IU/mL
(<104 copies/mL)
• No treatment
• Monitor HBV DNA and 
ALT/ 1–3 months
Monitor HBV DNA 
and ALT/1-3 months 
post-therapy
Continued monitoring 
to recognize delayed 
response or plan 
other strategy
HBeAg-Negative
ALT >2 × ULN ALT 1-2 × ULN ALT Normal ALT Normal
HBV DNA ≥2,000 IU/mL
(≥104 copies/mL)
• No treatment
• Monitor HBV DNA 
and ALT/3 months
Response Non-response
• Treatment if persistent 
(3-6 months) or has 
concerns of hepatic 
decompensation
• IFN based-therapy,
entecavir, adefovir,            
telbivudine, lamivudine,
• Long-term oral antiviral 
treatment usually 
required
• Liver biopsy if patient >40 years
• Treat if moderate or greater 
inflammation or fibrosis on biopsy
• No treatment
• Monitor HBV DNA and ALT/ 
6-12 months
Patients at risk: HCC surveillance
• AFP and ultrasonography/6 months
Fig. 2 Algorithm for the
management of hepatitis B e
antigen (HBeAg)-negative
patients with chronic hepatitis B
infection. AFP:
alphafetoprotein; ALT: alanine
aminotransferase; HBV:
hepatitis B virus; HCC:
hepatocellular carcinoma; ULN:
upper limit of normal
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123Patients with a rising trend in ALT (from normal or
minimally elevated levels) or with ALT[5 times ULN
may be developing an exacerbation and severe hepatitis or
hepatic decompensation may follow, particularly those
with increasing serum HBV-DNA[10
8 copies/ml [116]
or in patients with advanced ﬁbrosis [20]. They should be
monitored closely for weekly or biweekly serum bilirubin
levels and prothrombin time measurement. Treatment must
be initiated in time to prevent the development or deteri-
oration of hepatic decompensation. Such exacerbations,
particularly in patients with declining serum HBV-DNA
levels or a level less than 10
6 copies/ml, may also precede
spontaneous HBeAg seroconversion and may be followed
by disease remission [9]. Due to this, it is reasonable to
delay treatment for an observation period of 3 months if
there is no concern about hepatic decompensation.
Recommendation 4: Chronic HBV-infected patients with
ALT[2 times ULN and HBV-DNA[2.0 9 10
4 IU/ml
(10
5copies/ml) if HBeAg positive or[2.0 9 10
3 IU/ml(10
4
copies/ml) if HBeAg negative should be considered for
treatment (I). Treatment should be started as early as pos-
sible in case of impending or overt hepatic decompensation
(II). Otherwise, 3–6 months’ observation is recommended
(II).
Which drugs or strategy?
Drugs currently approved for the treatment of chronic HBV
infection have relatively limited sustained long-term efﬁ-
cacy. Therefore, the probability of sustained response, age
of patient, severity of liver disease, likelihood of drug
resistance, adverse events, and complications need to be
carefully considered. Conventional IFN or PegIFN-a2a,
lamivudine, adefovir, entecavir, and telbivudine can all be
considered for initial therapy in patients without liver
decompensation. The rates of sustained response seem to
be higher with IFN-a and PegIFN-a2a than with direct
antiviral agents, and response can be achieved with a
deﬁned duration of treatment [117]. Cirrhotic patients
respond to IFN or PegIFN better than, or at least as good
as, their noncirrhotic counterparts. IFN-based therapy has
more side effects and requires closer monitoring.
For viremic patients (both HBeAg positive and HBeAg
negative, adults and children) with ALT[5 times ULN,
entecavir, telbivudine, or lamivudine is recommended if
there is a concern about hepatic decompensation because of
its rapidity of action. IFN-based therapy is also more
effective in patients with higher ALT levels; it is generally
not preferred in such circumstances because its therapeutic
effect is not immediate and the patient may become
decompensated.
For HBeAg-positive patients with an ALT level between
2 and 5 times ULN, the choice between IFN-based therapy
and direct antiviral agents is less clear and either agent may
be used. Theoretically, this group of patients has not
mounted a high enough immune response against HBV,
and thus need immunomodulation.
Corticosteroid priming before IFN or lamivudine ther-
apy is generally not recommended and should be used
cautiously and only in expert centers and not in patients
with advanced disease.
HBV-DNA<2x103 IU/ml
(< 104 cp/ml)
Hepatitis flare
Liver cirrhosis
Decompensated Compensated
HBV-DNA>2x103 IU/ml
(> 104 cp/ml)
Antiviral therapy
Consider transplant
ALT, HBeAg or HBV-DNA
/3months
IFN based
ETV
ADV
Ldt
LAM
ETV
Ldt
LAM
ADV
ETV
Ldt
LAM
Conventional 
supportive 
treatment
Yes No
HCC surveillance
AFP and ultrasonography
/3-6months
Fig. 3 Algorithm for the
management of chronic
hepatitis B infection with liver
cirrhosis. ADV: adefovir; AFP:
alphafetoprotein; ALT: alanine
aminotransferase; ETV:
entecavir; HBeAg: hepatitis B e
antigen; HBV: hepatitis B virus;
HCC: hepatocellular carcinoma;
IFN: interferon; LAM:
lamivudine; Ldt: telbivudine
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sustained response rates than direct antiviral agents in
HBeAg-negative patients with intermittent or persistent
ALT elevation, moderate to severe inﬂammation, ﬁbrosis
on biopsy, and serum HBV-DNA[2,000 IU/ml (10
4
copies/ml). Direct antiviral agents provide other options,
but long-term therapy is required and therefore the drug
resistance proﬁle of the drug to be used should be con-
sidered. The long-term ([5 years) effect of IFN therapy is
better known than direct antiviral agents.
The decision as to which agent to be used should be an
individual one, based on disease severity, history of ﬂares,
hepatic function, the rapidity of drug action, resistance
proﬁle, side effects, costs of the drugs, and patient choice.
PegIFN-a2b has been approved for the treatment of
chronic HBV infection in a few countries. This IFN has not
been well studied in HBeAg-negative patients.
Recommendation 5: Patients can be treated with conven-
tional IFN 5–10 MU 3 times per week or PegIFN-a2a 90–
180 lg weekly (I), entecavir 0.5 mg daily (I), adefovir 10 mg
daily (I), telbivudine 600 mg daily (I), or lamivudine 100 mg
daily(I).Thymosina1.6 mg2 timesperweekcanalsobeused
(I).Lamivudineisrecommendedifthereisaconcernregarding
ensuing or overt hepatic decompensation (II). Entecavir and
telbivudine may also be used in this situation (IV).
How to monitor?
To achieve the most cost-effective treatment, adequate
monitoring during and after treatment is crucial. HBV-
DNA measurements should be done using assays stan-
dardized/validated to report against the WHO IU/ml
reference standard. If affordable, drug-resistant testing
should also be considered.
Recommendation 6: During therapy, ALT HBeAg and/or
HBV-DNA should be monitored at least every 3 months (I).
Renal function should be monitored if adefovir is used (I).
During IFN therapy, monitoring of adverse effects is
mandatory (I).
Recommendation 7: After the end of therapy, levels of
ALT and HBV-DNA should be monitored monthly for the
ﬁrst 3 months to detect early relapse, and then every 3 (for
cirrhotic patients and those who remain HBeAg/HBV-DNA
positive) to 6 months (for responders) (II). For nonre-
sponders, further monitoring of HBV markers is required to
both recognize a delayed response and plan retreatment
when indicated (II).
When to stop therapy?
The recommended duration of IFN-based therapy for
patients with HBeAg-positive hepatitis infection is
6–12 months irrespective of whether or not response has
occurred. For HBeAg-negative patients, 12 months’ ther-
apy is required. A 6- to 12-month observation period after
the end of IFN therapy is also recommended to both detect
delayed response and establish whether a response is sus-
tained, and thus whether retreatment or other therapy is
required. The recommended duration of thymosin a1
therapy is 6 months, with 12 months’ observation after end
of therapy.
Since the incidence of drug resistance increases with
increasing duration of direct antiviral therapy, therapy can
be stopped if the patient has undergone HBeAg serocon-
version with HBV-DNA loss measured at two consecutive
occasions at least 6 months apart. For those who remain
HBeAg positive, the decision to continue or stop therapy
should be evaluated individually on the basis of clinical/
virologic response and disease severity. If resistant muta-
tions emerge, early rescue therapy with other agents is
indicated. For HBeAg-negative patients, the optimal
duration of treatment is unknown and the decision to stop
therapy should be determined by clinical response and
severity of the underlying liver disease.
Recommendation 8: For conventional IFN, the current
recommended duration of therapy is 4–6 months for
HBeAg-positive patients (II) and at least a year for HBeAg-
negative patients (I). For PegIFN, the recommended
duration is at least 6 month for HBeAg-positive patients
(II) and 12 months for HBeAg-negative patients (I). For
thymosin a1, the recommended duration of therapy is
6 months for both HBeAg-positive (I) and HBeAg-negative
patients (II).
Recommendation 9: For oral antiviral agents: In
HBeAg-positive patients, treatment can be stopped when
HBeAg seroconversion with undetectable HBV-DNA has
been documented on 2 separate occasions at least
6 months apart (II). In HBeAg-negative patients, it is not
clear how long this treatment should be continued, but
treatment discontinuation can be considered if undetect-
able HBV-DNA has been documented on three separate
occasions 6 months apart. (II).
What to do for patients in special circumstances?
Female patients in the childbearing age
When treatment is indicated in women in the childbearing
age, both the drug property and the duration of dosing
should be considered.
Recommendation 10: For female patients of childbear-
ing age, IFN-based therapy is preferred for nonpregnant
women and pregnancy is discouraged during IFN therapy.
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123Women who become pregnant while on oral antiviral
drug(s) can continue treatment with category B drug(s)
(VI).
Patients with concurrent HIV infection
All HIV-infected patients with active HBV replication and
elevated serum ALT levels may be considered for treat-
ment. Treatment needs to be individualized according to
the patient’s HIV status. If the infection does not fulﬁll
treatment criteria, IFN-based therapy or adefovir mono-
therapy is preferred. Lamivudine or tenofovir monotherapy
is not recommended in this setting because of the risk of
HIV resistance. HAART containing lamivudine/tenofovir
or its equivalent combination is recommended if treatment
is being continued for infection.
Recommendation 11: Adefovir, telbivudine, or IFN (if
CD4[500) is preferred if patient’s HIV infection does not
require treatment. If infection requires treatment, tenofovir
or lamivudine/tenofovir combination should be included in
the active antiretroviral therapy (II).
Patients with concurrent HCV or HDV infection
It is important to determine which virus is dominant before
designing the treatment strategy.
Recommendation 12: In patients with concurrent HCV
or HDV infection, determine which virus is dominant and
treat the patients accordingly (III).
Patients with decompensated liver disease
IFN is usually contraindicated in patients with decompen-
sated liver disease. Direct antiviral agent with potent and
prompt HBV suppressive action should be used
immediately.
Recommendation 13: Lamivudine is the agent of choice
for treatment-naı¨ve patients with obvious or impending
hepatic decompensation (II). Entecavir and telbivudine can
also be used (IV).
Patients undergoing immunosuppression or chemotherapy
HBV reactivation is a serious complication in patients
undergoing immunosuppression or chemotherapy. Lami-
vudine therapy is effective when instituted early, before the
occurrence of clinical jaundice and decompensation.
Results are signiﬁcantly better if lamivudine is used before
starting chemotherapy [118]. Prophylactic treatment using
other antiviral agent has not been reported.
Recommendation 14: Before receiving immunosuppres-
sion or chemotherapy, patients should be screened for
HBsAg (III). If HBsAg positive, prophylactic therapy with
lamivudine before the start and up to at least 12 weeks
after the end of immunosuppression or chemotherapy is
recommended (I). Other direct antiviral agents can also be
used (IV).
Patients with drug resistance
Once drug resistance is evident by a more than 1 log IU/ml
increase of HBV-DNA from nadir, rescue therapy should
be instituted as early as possible.
Recommendation 15: For patients who develop drug
resistance while on lamivudine, add-on adefovir therapy is
indicated (I); switching to entecavir (1 mg/day) is an
option (I). For lamivudine-naı¨ve patients who develop drug
resistance while on adefovir, add-on or switching to lam-
ivudine, telbivudine, or entecavir is indicated (III). For
patients who develop drug resistance while on telbivudine,
add-on adefovir therapy is indicated (IV). Switching to
IFN-based therapy is an option (III).
Patients in the setting of liver transplantation
Nucleos(t)ide analogues are effective in pretransplant
treatment, prevention (in combination with HBIg) of
posttransplant HBV recurrence, and treatment of post-
transplant HBV-related allograft infection. Adequate use of
these agents has improved the outcome.
Recommendation 16–1: Nucleos(t)ide analogue(s)
should be commenced in all patients with HBV-associated
liver failure who are listed for transplantation and have
detectable HBV-DNA. Lamivudine plus low-dose HBIg
(400–800 U i.m. daily for 1 week, followed by 400–800 U
monthly for long term) provides safe and effective prophy-
laxis against HBV reinfection of the allograft (II).
Alternatively, lamivudine + adefovir prophylaxis can be
considered (II).
Recommendation 16–2: Late (at least 12 months post-
transplant) HBIg substitution by adefovir provides safe and
cost-effective prophylaxis (II). Late conversion to lamivu-
dine monotherapy may be considered in ‘‘low-risk’’
patients (I).
Recommendation 16–3: HBV-naı¨ve patient receiving a
liver from anti-HBc(+) donor should receive long-term
prophylaxis with either lamivudine or HBIg (III).
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123Unresolved issues and areas for further study
Despite recent advances in the treatment of chronic HBV
infection, the results are still unsatisfactory. In particular,
the following issues remain unsettled:
1. Should HBV genotyping be routine in designing
treatment plan?
2. What should be done if on-treatment response to direct
antiviral agents (at 24 week?) is not satisfactory?
3. What should be the treatment strategy for children with
chronic HBV infection? ‘‘Necessity’’ or ‘‘likelihood to
respond’’?
4. Is there more effective therapy for patients with
chronic HDV infection?
5. What is the role of corticosteroid withdrawal, lamivu-
dine pulse therapy, or other immunomodulating agents
and modes of immunomodulation?
6. What is the optimal combination therapy to enhance
efﬁcacy?
7. Cost-effectiveness of each therapeutic strategy.
The development of new drugs and new strategies,
especially combination or sequential antiviral therapy, is
the highest priority in further improving the outcomes of
treatment.
Acknowledgment The expert pre-meeting was sponsored by the
Liver Society of Thailand.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Liaw YF, Leung N, Guan R, Lau GKK, Merican I, McCaughan G
et al. Asian-Paciﬁc consensus statement on the management of
chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–489.
2. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P,
Schiff ER et al. A treatment algorithm for the management of
chronic hepatitis B virus infection in the United States: an
update. Clin Gastroenterol Hepatol 2006;4:936–962.
3. ACT-HBV Asia-Paciﬁc Steering Committee Members. Chronic
hepatitis B: treatment alert. Liver Int 2006;26:47–58.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
2007;45:507–539.
5. Summers J, Mason WS. Replication of the genome of a hepatitis
B-like virus by reverse transcription of an RNA intermediate.
Cell 1982;29:403–415.
6. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J.
Changes of hepatitis B virus DNA in liver and serum caused by
recombinant leukocyte interferon treatment: analysis of intra-
hepatic replicative hepatitis B virus DNA. Hepatology
1985;5:728–734.
7. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L et al.
Natural history and disease progression in Chinese chronic
hepatitis B patients in immune-tolerant phase. Hepatology
2007;46:395–401.
8. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical
signiﬁcance of persistently normal ALT in chronic hepatitis B
infection. J Hepatol 2007;47:760–767.
9. Liaw YF. Hepatitis ﬂares and hepatitis B e antigen serocon-
version: implication in anti-hepatitis B virus therapy.
J Gastroenterol Hepatol 2003;18:246–252.
10. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is
associated with a higher risk of reactivation of hepatitis B,
progression to cirrhosis than genotype B: a longitudinal study of
hepatitis B e antigen-positive patients with normal aminotrans-
ferase levels at baseline. J Hepatol 2005;43:411–417.
11. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of
hepatitis B e antigen to antibody seroconversion in patients with
normal serum aminotransferase levels. Am J Med
2004;116:829–834.
12. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM.
Long-term outcome after spontaneous HBeAg seroconversion in
patients with chronic hepatitis B. Hepatology 2002;35:1522–
1527.
13. Chu CM, Liaw YF. Predictive factors for reactivation of hepa-
titis B following hepatitis B e antigen seroconversion in chronic
hepatitis B. Gastroenterology 2007;133:1458–1465.
14. Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive
HBsAg carriers. Hepatol Int 2007;1:311–315.
15. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote
EJ. Hepatitis B virus DNA prediction rules for hepatitis B e
antigen-negative chronic hepatitis B. Hepatology 2007;46:1057–
1070.
16. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cir-
rhosis in patients with chronic type B hepatitis: a prospective
study. Hepatology 1988;8:493–496.
17. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM et al.
Interferon therapy in HBeAg positive chronic hepatitis reduces
cirrhosisandhepatocellularcarcinoma.JHepatol2007:46:45–52.
18. Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM et al.
Long-term outcome of chronic hepatitis B based on histological
grade and stage. J Gastroenterol Hepatol 2007;22:383–388.
19. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following
the onset of cirrhosis in patients with chronic hepatitis B: a long-
term follow-up study. Hepatol Int 2007;1:267–273.
20. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural
history and treatment. Semin Liver Dis 2006;26:142–152.
21. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY et al.
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N
Engl J Med 2002;347:168–174.
22. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ et al.
Hepatitis B virus genotype and DNA level and hepatocellular
carcinoma: a prospective study in men. J Natl Cancer Inst
2005;97:265–272.
23. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ et al.
Predicting cirrhosis risk based on the level of circulating hepa-
titis B viral load. Gastroenterology 2006;130:678–686.
24. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of
hepatocellular carcinoma across a biological gradient of serum
hepatitis B virus DNA level. JAMA 2006;295:65–73.
25. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ et al.
Temporal relationship between hepatitis B virus enhancer II/
basal core promoter sequence variation and risk of hepatocel-
lular carcinoma. Gut 2008;57:91–97.
26. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic
carriers of high endemic areas: appreciably high rates during a
long-term follow up. Hepatology 2007;45:1187–1192.
27. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following
spontaneous HBsAg seroclearance in chronic hepatitis B
280 Hepatol Int (2008) 2:263–283
123patients with or without concurrent infection. Gastroenterology
2002;123:1084–1089.
28. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ et al.
HBsAg seroclearance in chronic hepatitis B in the Chinese:
virological, histological, and clinical aspects. Hepatology
2004;39:1694–1701.
29. Kao JH. Role of viral factors in the natural course and therapy of
chronic hepatitis B. Hepatol Int 2007;1:415–430.
30. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball
MM, Cagle HH et al. Clearance of hepatitis B e antigen in
patients with chronic hepatitis B and genotypes A, B, C, D, and
F. Gastroenterology 2007;133:1452–1457.
31. Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH et al.
Clinical relevance of hepatitis B virus genotype in children with
chronic infection and hepatocellular carcinoma. Gastroenterol-
ogy 2004;127:1733–1738.
32. Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H
et al. Inﬂuence of viral load and genotype in the progression of
hepatitis B-associated liver cirrhosis to hepatocellular carci-
noma. Liver Int 2005;25:220–225.
33. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus
genotypes and spontaneous hepatitis B e antigen seroconver-
sion in Taiwanese hepatitis B carriers. J Med Virol 2004;
72:363–369.
34. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW
et al. Genotype C hepatitis B virus infection is associated with
an increased risk of hepatocellular carcinoma. Gut
2004;53:1494–1498.
35. Yuen MF, Wong DK, Zheng BJ, Chan CC, Yuen JC, Wong BC
et al. Difference in T helper responses during hepatitis ﬂares in
hepatitis B e antigen (HBeAg)-positive patients with genotypes
B and C: implication for early HBeAg seroconversion. J Viral
Hepat 2007;14:269–275.
36. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Pro-
ﬁle, spectrum and signiﬁcance of HBV genotypes in chronic
liver disease patients in the Indian subcontinent. J Gastroenterol
Hepatol 2002;17:165–170.
37. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter
mutations of hepatitis B virus increase the risk of hepatocellular
carcinoma in hepatitis B carriers. Gastroenterology 2003;
124:327–334.
38. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC et al.
Pre-S deletion and complex mutations of hepatitis B virus
related to advanced liver disease in HBeAg-negative patients.
Gastroenterology 2007;133:1466–1474.
39. Chien RN. Current therapy for hepatitis C or D or immunode-
ﬁciency virus concurrent infection with chronic hepatitis B.
Hepatol Int 2008. doi:10.1007/s12072-008-9066-1.
40. Liaw YF. Hepatitis B virus replication and liver disease pro-
gression: the impact of antiviral therapy. Antivir Ther 2006;
11:669–679.
41. Piratvisuth T. Immunomodulator therapy of chronic hepatitis B.
Hepatol Int 2008. doi:10.1007/s12072-008-9046-5.
42. Iorio R, Giannattasio A, Cirillo F, D’Alessandro L, Vegnente A.
Long-term outcome in children with chronic hepatitis B: a 24-
year observation period. Clin Infect Dis 2007;45:943–949.
43. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T.
Sequential combination of glucocorticosteroids and alfa inter-
feron versus alfa interferon alone for HBeAg-positive chronic
hepatitis B. Cochrane Database Syst Rev 2005;(3):CD000345.
Review.
44. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM,
Mohr L et al. Long-term follow-up of HBeAg-positive patients
treated with interferon alfa for chronic hepatitis B. N Engl J Med
1996;334:1422–1427.
45. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term
outcome of interferon-alpha treated and untreated patients with
HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306–
313.
46. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC,
Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an
advance in the treatment of hepatitis B e antigen-positive
chronic hepatitis B. J Viral Hepat 2003;10:298–305.
47. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S,
Cooksley G et al. Peginterferon alfa-2a, lamivudine, and the
combination for HBeAg-positive chronic hepatitis B. N Engl J
Med 2005;352:2682–2695.
48. Marcellin P, Lau GKK Bonino F et al. Peginterferon alfa-2a
alone, lamivudine alone and the two in combination in patients
with HBeAg negative chronic hepatitis B. N Engl J Med
2004;351:1206–1217.
49. Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB
et al. Sustained response to peginterferon alfa-2a (40 kDa) with
or without lamivudine in Asian patients with HBeAg-positive
and HBeAg-negative chronic hepatitis B. Hepatol Int
2008;2:102–110.
50. Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C,
Michielsen PP et al. Peginterferon alpha-2b is safe and effective
in HBeAg-positive chronic hepatitis B patients with advanced
ﬁbrosis. Hepatology 2007;46:388–394.
51. Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H,
Karayalcin S et al. Successful treatment with peginterferon alfa-
2b of HBeAg-positive HBV non-responders to standard inter-
feron or lamivudine. Am J Gastroenterol 2006;101:2523–2529.
52. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man
RA, Schalm SW et al. Flares in chronic hepatitis B patients
induced by the host or the virus? Relation to treatment response
during Peg-interferon {alpha}-2b therapy. Gut 2005;54:1604–
1609.
53. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC,
Cooksley G et al. HBeAg and hepatitis B virus DNA as outcome
predictors during therapy with peginterferon alfa-2a for HBeAg-
positive chronic hepatitis B. Hepatology 2008;47:428–434.
54. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Pirat-
visuth T et al. Predicting response to peginterferon alpha-2a,
lamivudine and the two combined for HBeAg-negative chronic
hepatitis B. Gut 2007;56:699–705.
55. Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca
US, Cakaloglu Y et al. Pegylated interferon alfa-2b alone or in
combination with lamivudine for HBeAg-positive chronic hep-
atitis B: a randomised trial. Lancet 2005;365:123–129.
56. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma
BC et al. Effect of lowering HBV DNA levels by initial antiviral
therapy before adding immunomodulator on treatment of
chronic hepatitis B. Am J Gastroenterol 2007;102:96–104.
57. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A et al.
A randomized, placebo-controlled trial of thymosin-alpha1 and
lymphoblastoid interferon for HBeAg-positive chronic hepatitis
B. Antivir Ther 2006;11:245–253.
58. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efﬁcacy of
thymosin a1 in patients with chronic type B hepatitis: a ran-
domized controlled trial. Hepatology 1998;27:1383–1387.
59. You J, Zhuang L, Cheng HY, Yan SM, Qiao YW, Huang JH
et al. A randomized, controlled, clinical study of thymosin
alpha-1 versus interferon-alpha in [corrected] patients with
chronic hepatitis B lacking HBeAg in China [corrected] J Chin
Med Assoc 2005;68:65–72.
60. Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus
genotypes B is associated with better response to thymosin a1
therapy than genotype C. J Viral Hepat 2006;13:845–850.
Hepatol Int (2008) 2:263–283 281
12361. Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M
et al. The efﬁcacy and safety of thymosin alpha-1 in Japanese
patients with chronic hepatitis B; results from a randomized
clinical trial. J Viral Hepat 2005;12:300–306.
62. Chan HL, Tang JL, Tam W, Sung JJ. The efﬁcacy of thymosin
in the treatment of chronic hepatitis B virus infection: a meta-
analysis. Aliment Pharmacol Ther 2001;15:1899–1905.
63. Vandepapeli’ere P, Lau GKK, Leroux-Roels G, Horsmans Y,
Gane E, Tawandee T et al. Therapeutic vaccination of chronic
hepatitis B patients with virus suppression by antiviral therapy: a
randomized, controlled study of co-administration of HBsAg/
AS02 candidate vaccine and lamivudine. Vaccine 2007;25:
8585–8597.
64. Leung N. Recent data on treatment of chronic hepatitis B
with nucleos(t)ide analogues. Hepatol Int 2008. doi:10.1007/
s12072-008-9061-6.
65. Liaw YF. Results of lamivudine trials in Asia. J Hepatol
2003;39:S111–S115.
66. Jonas MM, Little NR, Gardner SD, Members of the Interna-
tional Pediatric Lamivudine Investigator Group*. Long-term
lamivudine treatment of children with chronic hepatitis B:
durability of therapeutic responses and safety. J Viral Hepat
2008;15:20–27.
67. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. The deter-
minants for sustained HBeAg response to lamivudine therapy.
Hepatology 2003;38:1267–1273.
68. Chein RN, Liaw YF. Short-term lamivudine therapy in HBeAg-
negative chronic active hepatitis B in Taiwan. Antivir Ther
2006;11:947–952.
69. Fung SK, Wong F, Hussain M, Lok AS. Sustained response
after a 2-year course of lamivudine treatment of hepatitis B e
antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:
432–438.
70. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lam-
ivudine treatment for hepatitis B e antigen-negative chronic
hepatitis B: a double-blind, placebo-controlled trial. Antivir
Ther 2007;12:345–353.
71. Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H
et al. Lamivudine for patients with chronic hepatitis B and
advanced liver disease. N Engl J Med 2004;351:1521–1531.
72. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG,
Pawlotsky JM et al. Antiviral drug-resistant HBV: standardiza-
tion of nomenclature and assays and recommendations for
management. Hepatology 2007;46:254–265.
73. Locarnini S. Primary resistance, multidrug resistance and cross-
resistance pathways in HBV as a consequence of treatment
failure. Hepatol Int 2008. doi:10.1007/s12072-008-9048-3.
74. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exac-
erbation and hepatitis B virus clearance after emergence of
YMDD motif mutation during lamivudine therapy. Hepatology
1999;30:567–572.
75. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the ori-
ginal hepatitis B virus YMDD-motif mutants with emergence of
distinct lamivudine-resistant mutants during prolonged lamivu-
dine therapy. Hepatology 2000;31:1318–1326.
76. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY et al.
Extended lamivudine treatment in patients with chronic hepatitis
B enhances hepatitis B e antigen seroconversion rates: results
after 3 years of therapy. Hepatology 2001;33:1527–1532.
77. Di Marco V, Marzano A, Lampertico P, Andreone P, Santan-
tonio T, Almasio PL et al. Clinical outcome of HBeAg-negative
chronic hepatitis B in relation to virological response to lami-
vudine. Hepatology 2004;40:883–891.
78. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone
priming enhances Th1 response and efﬁcacy of subsequent
lamivudine therapy in patients with chronic hepatitis B. Hepa-
tology 2000;32:604–609.
79. Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V.
Beneﬁcial effects of ‘‘lamivudine pulse’’ therapy in HBeAg
positive patients with normal ALT. J Viral Hepat 2004;11:552–
558.
80. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT,
Kitis G, Rizzetto M et al. Long-term therapy with adefovir
dipivoxil for HBeAg-negative chronic hepatitis B for up to
5 years. Gastroenterology 2006;131:1743–1751.
81. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir
monotherapy after emergence of lamivudine resistant muta-
tions in patients with liver cirrhosis. J Viral Hepat 2006;13:
250–255.
82. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus
switching-to adefovir therapy in lamivudine-resistant HBeAg-
negative chronic hepatitis B. Hepatology 2007;45:307–313.
83. Lampertico P, Vigano ` M, Manenti E, Iavarone M, Sablon E,
Colombo M. Low resistance to adefovir combined with lami-
vudine: a 3-year study of 145 lamivudine-resistant hepatitis B
patients. Gastroenterology 2007;133:1445–1451.
84. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G,
Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-
negative patients developing genotypic resistance to lamivudine.
Hepatology 2005;42:1414–1419.
85. Liaw YF. Rescue therapy for lamivudine-resistant chronic
hepatitis B: when and how? Hepatology 2007;26:266–268.
86. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC
et al. A comparison of entecavir and lamivudine for HBeAg-
positive chronic hepatitis B. N Engl J Med 2006;354:1001–1010.
87. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman
Z et al. Entecavir versus lamivudine for patients with HBeAg-
negative chronic hepatitis B. N Engl J Med 2006;354:1011–
1020.
88. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J
et al. Entecavir therapy for up to 96 weeks in patients with
HBeAg-positive chronic hepatitis B. Gastroenterology
2007;133:1437–1444.
89. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Ci-
anciara J et al. Entecavir for treatment of lamivudine-refractory,
HBeAg-positive chronic hepatitis B. Gastroenterology
2006;130:2039–2049.
90. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y,
et al. Telbivudine versus lamivudine in patients with chronic
hepatitis B. N Engl J Med 2007;357:2576–2588.
91. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon
YM et al. Treatment of hepatitis B e antigen positive chronic
hepatitis with telbivudine or adefovir: a randomized trial. Ann
Intern Med 2007;147:745–754.
92. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH et al.
Twenty-four-week clevudine therapy showed potent and sus-
tained antiviral activity in HBeAg-positive chronic hepatitis B.
Hepatology 2007;45:1172–1178.
93. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS et al.
Clevudine is highly efﬁcacious in hepatitis B e antigen-negative
chronic hepatitis B with durable off-therapy viral suppression.
Hepatology 2007;46:1041–1048.
94. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A,
Schurmann D et al. Comparison of adefovir and tenofovir in the
treatment of lamivudine-resistant hepatitis B virus infection.
Hepatology 2004;40:1421–1425.
95. Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger
antiviral effect than adefovir (ADV) against lamivudine (LAM)
resistant hepatitis B virus (HBV). Hepatol Int 2008. doi:
10.1007/s12072-008-9045-6.
282 Hepatol Int (2008) 2:263–283
12396. Marcellin P, Heathcote J, Gane E, Balabanska R, Husa P, Gurel
S, et al. Tenofovir disoproxil fumarate (TDF) demonstrated
superior antiviral efﬁcacy to adefovir dipivoxil in two pivotal,
randomized, double-blind, studies for the treatment of HBeAg-
negative and HBeAg-positive chronic hepatitis B (CHB): study
102 and study 103. Hepatol Int 2008;2:A139.
97. Gane E. The roadmap concept: using early on-treatment viro-
logic responses to optimize long-term outcomes for patients
with chronic hepatitis B. Hepatol Int 2008; In press.
98. Dan YY, Aung MO, Lim SG. The economics of treating chronic
hepatitis B in Asia. Hepatol Int 2008; In press.
99. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Man-
agement of hepatitis B: summary of a clinical research
workshop. Hepatology 2007;45:1056–1075.
100. Farci P, Chessa C, Balestrieri C, Serra G, Lai ME. Treatment of
chronic hepatitis D. J Viral Hepat 2007;14(Suppl 1):58–63.
101. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A
et al. Efﬁcacy of interferon alpha-2b and lamivudine combina-
tion treatment in comparison to interferon alpha-2b alone in
chronic delta hepatitis: a randomized trial. J Gastroenterol
Hepatol 2006;21:657–663.
102. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy
in hepatic decompensation during acute exacerbation of chronic
hepatitis B. J Hepatol 2003;38:322–327.
103. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T,
Rakela J et al. Determinants of early mortality in patients with
decompensated chronic hepatitis B treated with antiviral ther-
apy. Gastroenterology 2002;123:719–727.
104. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil
therapy for lamivudine-resistant hepatitis B in pre- and post-
liver transplantation. Hepatology 2003;38:1419–1427.
105. Sokal E, Kelly D, Wirth S, Mizerski J, Lu B, Kleber K et al. The
pharmacokinetics (PK) and safety of a single dose of adefovir
dipivoxil (ADV) in children and adolescents aged 2–17 with
chronic hepatitis B. J Heptol 2004;40(Suppl 1):132.
106. Lau GKK. Hepatitis B reactivation after chemotherapy—two
decades of clinical research. Hepatol Int 2008. doi:
10.1007/s12072-008-9056-3.
107. Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH et al.
Transarterial chemo-lipiodolization can reactivate hepatitis B
virus replication in patients with hepatocellular carcinoma.
J Hepatol 2004;41:427–435.
108. Hui CK, Cheung WWW, Au WY, Zhang HY, Yueng YH,
Leung N et al. Rituximab increases the risk of de novo hepatitis
B infection in hepatitis B surface antigen negative patients
undergoing cytotoxic chemotherapy. Gastroenterology
2006;131:59–68.
109. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey
GP et al. Lamivudine plus low-dose hepatitis B immunoglobulin
to prevent recurrent hepatitis B following liver transplantation.
Gastroenterology 2007;132:931–937.
110. Angus P, Strasser S, Patterson S, McCaughan G, Gane E. A
randomized study to assess the safety and efﬁcacy of adefovir
dipivoxil substitution for hepatitis B immune globulin in liver
transplantation patients receiving long-term low dose IM HBIg
and lamivudine prophylaxis. Hepatology 2007;46:238A.
111. Gane E, Strasser S, Patterson S, McCaughan G, Angus P. A
prospective study on the safety and efﬁcacy of lamivudine and
adefovir prophylaxis in HBsAg positive liver transplantation
candidates. Hepatology 2007;46:479A.
112. Ong SC, Mak B, Aung MO, Li SC, Lim SG. Health-related
quality of life in chronic hepatitis B patients. Hepatology
2008;47:1108–1117.
113. Han KH. Chronic HBV infection with persistently normal ALT:
not to treat. Hepatol Int 2008. doi:10.1007/s12072-008-9068-z.
114. Liaw YF. Prevention and surveillance of hepatitis B virus-
related hepatocellular carcinoma. Semin Liver Dis
2005;25(Suppl 1):40–47.
115. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired
in childhood: special emphasis on prognostic and therapeutic
implication of delayed HBeAg seroconversion. J Viral Hepat
2007;14:147–152.
116. Sheen IS, Hsu CW, Chen YC, Yeh CT, Chu CM, Liaw YF.
Timing of lamivudine in treating acute exacerbation of chronic
hepatitis B: role of HBV viral load. Hepatol Int 2007;1:125.
117. Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global
health problem requiring coherent worldwide treatment strate-
gies. Hepatol Int 2007;1:316–325.
118. Hsu C, Hsiung C, Su IJ, Hwang WS, Wang MC, Lin SF et al. A
revisit for prophylactic lamivudine for chemotherapy-associated
hepatitis B reactivation in non-Hodgkin’s lymphoma: a ran-
domized trial. Hepatology 2008;47:844–853.
Hepatol Int (2008) 2:263–283 283
123